Gain Therapeutics (NASDAQ:GANX) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Gain Therapeutics (NASDAQ:GANXGet Rating) issued its quarterly earnings results on Monday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06, reports. The firm had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.06 million. Gain Therapeutics had a negative return on equity of 38.81% and a negative net margin of 7,212.75%.

NASDAQ GANX opened at $2.66 on Thursday. The company has a current ratio of 14.78, a quick ratio of 14.78 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $3.67 and its two-hundred day moving average is $4.88. Gain Therapeutics has a 12-month low of $2.53 and a 12-month high of $11.00.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GANX. UBS Group AG boosted its stake in shares of Gain Therapeutics by 64.4% during the 3rd quarter. UBS Group AG now owns 6,740 shares of the company’s stock worth $51,000 after acquiring an additional 2,640 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Gain Therapeutics by 66.2% during the 2nd quarter. Millennium Management LLC now owns 23,878 shares of the company’s stock worth $239,000 after acquiring an additional 9,511 shares in the last quarter. Advisor Group Holdings Inc. purchased a new stake in shares of Gain Therapeutics during the 4th quarter worth approximately $54,000. Jane Street Group LLC purchased a new stake in shares of Gain Therapeutics during the 1st quarter worth approximately $48,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Gain Therapeutics during the 4th quarter worth approximately $70,000. Institutional investors own 8.89% of the company’s stock.

GANX has been the topic of several recent research reports. Zacks Investment Research upgraded Gain Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 1st. HC Wainwright initiated coverage on Gain Therapeutics in a research report on Tuesday, March 29th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, B. Riley dropped their price target on Gain Therapeutics from $21.00 to $16.00 and set a “buy” rating on the stock in a research report on Tuesday, March 29th.

About Gain Therapeutics (Get Rating)

Gain Therapeutics, Inc, a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.

Featured Stories

Earnings History for Gain Therapeutics (NASDAQ:GANX)

Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.